You have every right to feel that way - heartless leadership - no pun intended - 911 fire people, no press release for fda approval - late sec filings - on Friday the thirteenth - etc. However, it must come to an end soon because they do have a good product, abbott mentioned it during their call, there is FDA approval, they hired someone to look into options for a buyout/merger, etc, they are still selling the older test, and it is now time to take a shi$ or get off the pot. I am happy we will be at a cross roads on 31 March to know what we have or don't have and to sell or stay. I am taking the risk and no one owes me a thing
With BGMD, that is very likely. This company never fails to disappoint. Disappointment is their most reliably consistent outcome for shareholders. They will report #$%$ numbers in the ER at the last minute, they will not provide any meaningful guidance going forward. There will be no news of marketing or roll-out or G3, no news of ABT involvement. They will just muddle along as usual and let MM's drive the pps down every damn day until BK. It's best to short this t*urd if you can.
could not post whole abstract, heres the link
No routine tests currently exist to objectively diagnose mild traumatic brain injury mTBI /concussion. Previously reported biomarkers for mTBI represented proteins released from the damaged neurons or glia. However, the low levels of these proteins and/or the complexity of assays used for their detection limits the implementation of these biomarkers in routine practice. Here we sought to identify proteins whose synthesis is altered after mTBI and whose blood levels could be measured using standard immunoassays. Adult patients sustaining a concussion within the past 24 h were enrolled. Controls were uninjured subjects and patients with orthopedic injur OI. Four candidate biomarkers were identified: copeptin, galectin 3 LGALS3, matrix metalloproteinase 9 MMP9, and occludin OCLN. A 3.4-fold decrease p
Big victory for the shorts, while my explains and warnigs were deleted on this booard. But with BGMD the shorts will nevertheless have no success!
Sentiment: Strong Buy